Envestnet Portfolio Solutions Inc. Trims Stock Holdings in CVS Health Corporation $CVS

Envestnet Portfolio Solutions Inc. lessened its position in shares of CVS Health Corporation (NYSE:CVS) by 18.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 51,089 shares of the pharmacy operator’s stock after selling 11,538 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in CVS Health were worth $3,852,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of the company. Avion Wealth increased its holdings in CVS Health by 99.0% in the 2nd quarter. Avion Wealth now owns 380 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 189 shares during the period. Harbor Capital Advisors Inc. increased its stake in shares of CVS Health by 72.1% in the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 142 shares during the period. Corundum Trust Company INC purchased a new position in shares of CVS Health during the third quarter worth $29,000. Harbor Asset Planning Inc. acquired a new position in CVS Health during the second quarter valued at $30,000. Finally, Front Row Advisors LLC boosted its holdings in CVS Health by 436.5% in the second quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock valued at $31,000 after purchasing an additional 371 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Trading Up 0.4%

Shares of CVS opened at $83.02 on Monday. The firm’s fifty day moving average is $79.05 and its two-hundred day moving average is $74.84. The stock has a market cap of $105.39 billion, a PE ratio of 218.49, a price-to-earnings-growth ratio of 0.76 and a beta of 0.48. The company has a quick ratio of 0.63, a current ratio of 0.83 and a debt-to-equity ratio of 0.83. CVS Health Corporation has a 52-week low of $53.28 and a 52-week high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. The firm had revenue of $102.87 billion for the quarter, compared to analyst estimates of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. CVS Health’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Thursday, January 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Thursday, January 22nd. CVS Health’s payout ratio is currently 700.00%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CVS shares. UBS Group reissued an “outperform” rating on shares of CVS Health in a report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CVS Health in a research report on Monday, December 29th. Truist Financial set a $100.00 price objective on CVS Health in a research report on Wednesday, December 10th. TD Cowen lifted their target price on shares of CVS Health from $100.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Finally, Wells Fargo & Company dropped their price target on shares of CVS Health from $103.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 13th. Nineteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, CVS Health has an average rating of “Moderate Buy” and an average price target of $94.86.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is activating pharmacies and advising patients to pick up prescriptions ahead of a major winter storm — shows operational readiness and continuity of care that can limit service disruption and protect short‑term revenue. Read More.
• Positive Sentiment: CVS announced programs aimed at making health insurance “simpler and more affordable,” signaling potential member growth and pricing or mix improvements for its health-insurance businesses. Read More.
• Positive Sentiment: Operational/PBM changes: CVS said it will cut some prior‑authorization requirements and expand rebate‑sharing — moves that could reduce friction for care delivery, improve customer experience and blunt policy/competitive criticisms. Read More.
• Positive Sentiment: Strategic/innovation: CVS is partnering with the University of Maryland on AI and pharmacy workforce development — a long‑term positive for efficiency and talent pipeline in its retail and clinical operations. Read More.
• Positive Sentiment: Market positioning: Reports show heavy buying of CVS call options, indicating some investors are positioned for further upside in the near term. Read More.
• Neutral Sentiment: Legal outcome: A Bloomberg Law piece says CVS and UnitedHealth successfully defended against an antitrust suit over drug costs — a favorable legal development but not necessarily dispositive for broader PBM scrutiny. Read More.
• Negative Sentiment: House Judiciary Committee report accuses CVS/Caremark of thwarting competition and targeting independent pharmacies — the committee alleges anticompetitive PBM practices, escalating regulatory and litigation risk that could pressure margins and valuation. Read More.
• Negative Sentiment: Follow‑up coverage: Multiple outlets (Becker’s, Seeking Alpha, MSN) detail the committee’s findings and show CVS executives were scrutinized in hearings over high costs and PBM conduct — these stories amplify political and regulatory uncertainty that investors price as risk. Read More. Read More. Read More.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.